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Abstract
Background: HIV and tuberculosis (TB) are intricably interlinked in South Africa. The social aspects of this co-
epidemic remain relatively unexplored. More specifically, no research has quantitatively explored the double stigma
associated with HIV and TB in this context, and more specifically the impact of the co-epidemic on [1] the
stigmatisation of TB and [2] the TB stigma mangement strategy of covering (i.e. the use of TB as a cover for having
HIV). The current study aims to address this research gap by disentangling the complex mechanisms related to HIV-
TB stigma.
Methods: Using Structural Equation Modelling (SEM), data of 882 health care workers (HCWs) in the Free State
province, South Africa, are analysed to investigate the link between the stigmatization of HIV and TB and the stigma
management by those affected. The current study focuses on health care workers (HCWs), as both TB and HIV have
a severe impact on this professional group.
Results: The results demonstrate that the perceived link between the epidemics is significantly associated with
double HIV-TB stigmatization. Furthermore, the link between the illnesses and the double stigma are driving the
stigmatization of TB. Finally, the link between HIV and TB as well as the stigmatization of both diseases by
colleagues are associated with an increased use of covering as a stigma management strategy.
Conclusions: This is the first quantitative study disentagling the mediating role of double stigma in the context of
the co-epidemic as well as the impact of the co-epidemic on the social connotations of TB. The results stress the
need for an integrated approach in the fight against HIV and TB recognizing the intertwined nature of the co-
epidemic, not only in medical-clinical terms, but also in its social consequences.
Trial registration: South African National Clinical Trials Register, registration ID: DOH-27-1115-5204. Prospectively
registered on 26 August 2015.
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Background
HIV/AIDS and tuberculosis (TB) have merged into a
deadly co-epidemic in South Africa. In absolute num-
bers, the country has the highest number of people liv-
ing with HIV (7.0 million in 2016) [1–4]. In addition, it
has one of the most severe TB epidemics in the world,
with the highest incidence of TB (834 per 100,000 in
2015) and 19,613 reported cases of multi-drug resistant
TB in 2015 [5]. Both epidemics are intricately inter-
twined: approximately 73% of TB cases are co-infected
with HIV [6].
Ample research has addressed the clinical and health
system challenges of the HIV and TB co-epidemic [7, 8],
but – as Daftary (2012) rightfully pointed out – “the so-
cial aspects remain relatively unexplored” [9], especially
the potential stigma associated with HIV and TB in a
setting confronted with this dual epidemic. Evidence-
based knowledge on the double stigma generated by the
interlinked nature of both epidemics is urgently needed
as both HIV and TB stigma have been individually ex-
tensively associated with non-disclosure [10–12], delayed
health care [13–16], and ultimately worse (physical and
psychological) health outcomes [10, 14, 17–21].
TB/HIV stigma
Most studies on stigma, including those on HIV and TB
stigma, are rooted in the work of Erving Goffman. He
defined stigma as a discrediting social label that changes
an individual’s self-image and disqualifies him or her
from full social acceptance [22]. Goffman’s essay gener-
ated a plethora of research applying the concept to a
wide range of circumstances, ranging from homosexual-
ity to cancer, often with considerable variation in the
concept’s definition, rendering it vulnerable to the cri-
tique that the stigma concept was too vaguely defined
[23]. As a response, a more recent conceptualization by
Link and Phelan (2001) narrows Goffman’s broad con-
ception of stigma to the co-existence of its defining
components, namely labeling, stereotyping, separation,
status loss, and discrimination, all within a context in
which power is exercised [24, 25].
The concept of stigma has been profusely applied to
both HIV and TB. However, there has been little re-
search on how the interlinked natures of the HIV and
TB epidemics have impacted the stigmatization of both
illnesses [9, 26–28]. Even fewer studies have investigated
the occurrence of a “new” double stigma, despite Bond
and Nyblade stating that “TB stigma can no longer be
thought of, or addressed, separately from HIV stigma”
and encouraging researchers to study and disentangle
this double or compound stigma of HIV and TB [26].
A seminal article that responded to this call and ad-
dressed the construction and management of this double
stigma was written by Daftary [9]. In this article, in-
depth qualitative work examined the lived experience of
co-infection with HIV and TB from the perspective of
those affected in KwaZulu-Natal, South Africa. In the
country, the co-epidemic renders TB not only symbolic,
but also symptomatic of HIV [26, 27]: the symptoms as-
sociated with TB (e.g. weight loss) are also symptomatic
of HIV, providing “impetus to the construction of over-
lapping dual stigmas” [9]. Evidence indicates that each
raises different degrees of stigma, whereby TB appears
as temporary and blameless while HIV is culpable and
permanent. The stigmatization of HIV was thus greater
than that of TB [9].
However, the confluence of both epidemics alters the
situation: TB patients have emerged as a vulnerable
group as the co-epidemic – in the current research set-
ting, South Africa’s Free State province, 3 out of 4 TB
cases with a known HIV status are HIV-positive [29] –
renders them easy targets of HIV-related stigmatization.
The negative affects normally associated with HIV are
thus now – in the context of the co-epidemic – being
transferred to TB. In a final step, Daftary [9] connected
[1] the interlinked nature of both epidemics and [2] the
resulting construction of overlapping – double – stigmas
to [3] the social act of “covering” [9, 22]. “Covering” is a
social act whereby people deflect attention away from a
dominant stigmatizing attribute (in this case, HIV) by
drawing attention to something more socially acceptable
or less stigmatized (in this case, TB) [9, 22].
Despite the fact that several authors have asserted that,
in the context of the co-epidemic, TB stigma cannot be
studied separately from HIV stigma, there are – to the
best of our knowledge – no quantitative studies attempt-
ing to disentangle this new compound or double stigma
and its associations with TB stigma and TB stigma man-
agement. The current study aims to address this re-
search gap by unraveling a range of concepts that are
related to this double stigma. More specifically, we in-
tend to build a model that represents social reality, link-
ing the concepts raised by previous in-depth qualitative
work, namely the link between HIV and TB, between
the stigmatization of HIV and TB (double stigma) and
the impact this has on the stigmatization TB and finally
the potential reaction by those affected (covering). In
other words, we expect that the epidemiological link be-
tween the 2 diseases results in a link between the stig-
mas (copying netagive connotations of HIV to TB),
which in turn stimulates the stigmatization of TB and
impacts on the reactions of those affected by the co-
epidemic – i.e., by hiding a potential HIV-positive status
with TB (covering).
Health care workforce
The current study focuses on health care workers
(HCWs) as the dual burden of TB and HIV has a severe
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impact on these professionals. Occupational exposure to
TB constitutes a major health risk for HCWs [30, 31],
especially in resource-constrained settings where large
patient numbers and resulting overcrowded health facil-
ities combined with poorly implemented infection con-
trol strategies render HCWs three times more likely to
acquire TB than the general population [11, 32]. Conse-
quently, TB is officially classified as an occupational haz-
ard. The HIV epidemic equally affects the workforce
because of the mutually reinforcing epidemiology of
HIV and TB: estimates of the HIV prevalence among
South African HCWs range from 11.5 to 20.0% [33].
In this context, workplace health services for HIV and
TB are an essential part of any health system strengthen-
ing strategy [34]. Research has demonstrated that pro-
viding HIV and TB services to HCWs at work – in the
occupational health unit (OHU) – is cost-effective and
preferred by the majority of HCWs [35, 36]. Accord-
ingly, a joint World Health Organization-International
Labor Organization-UNAIDS policy document on the
provision of TB and HIV prevention and care for HCWs
explicitly recommends the on-site availability of such oc-
cupational health services for the entire workforce so
that full access to HIV and TB prevention, treatment,
care, and support can be attained for this vulnerable
group [37].
However, a review paper demonstrated that HIV-
and TB-related stigma and discrimination are “key
barriers to both the delivery of quality health services
by health providers and to their utilization by com-
munity members and health providers themselves”
[38]. Stigmatization in the health care setting can thus
have severe implications for HCWs and health facil-
ities when HIV-positive/TB-infected HCWs delay or
avoid care, causing increased morbidity and mortality
and further strain on an overburdened health system
[38]. It is thus important to include not only the
respondent’s stigmatizing attitudes, but also the per-
ceived stigmatizing attitudes of colleagues, as these
may shape the views and behaviors of the participat-
ing HCWs.
This unique position of the health care workforce –
bearing the burden of the co-epidemic on the front line
of the health system while being at risk of contracting
HIV and/or TB and consequent HIV and TB
stigmatization – renders a quantitative study on double
HIV-TB stigma among HCWs a clear research priority
[11]. The current research thus aims to study (1) the
interlinked nature of both epidemics and (2) the result-
ing construction of overlapping double stigmas (by the
respondent and by colleagues) to (3) the stigmatization
of TB (by the respondents and by colleagues) as well as
(4) the resulting social act of “covering” in a sample of
882 HCWs in the Free State province of South Africa.
Methods
The current study aims to explore the dynamics of
double stigma and its impact on TB stigma (manage-
ment) among HCWs by analyzing the baseline data of a
cluster randomized controlled trial – the HIV and TB
Stigma among Health Care Workers Study (HaTSaH
study). The study was approved by the Ethics Committee
of the Faculty of Health Science of the University of the
Free State (ECUFS 55/2015) and the Ethical Committee
for the Social Sciences and Humanities of the University
of Antwerp (SHW-15-28-03).
The overarching HaTSaH study aims to (1) scientif-
ically assess the extent and sources of HIV- and TB-
related stigma among the health care workforce and
(2) develop and test evidence-based stigma-reduction
interventions. For this goal, a study sample of 882
HCWs – both clinical staff (446) (doctors and nurses)
and non-clinical staff (436) (e.g. messengers, cleaners,
and administrators) – working in 8 hospitals in the
Free State was drawn from the health care workforce
register. The questionnaires were in Afrikaans, Seso-
tho or English. After obtaining written informed con-
sent from all participants, trained field workers
provided the participants with the standard question-
naires that were completed in a self-administered
process. Where literacy was low, the fieldworkers read the
questions aloud, but they were answered independently.
Measures
The current study aims to build a model that represents
social reality, linking the concepts raised by previous in-
depth qualitative work, namely:
 the link between HIV and TB (HIV-TB)
 the double stigma (HIV and TB) by the respondent
(DS-R)
 the perceived double stigma (HIV and TB) by
colleagues (DS-C)
 the stigma toward TB by the respondent (TBS-R)
 the perceived stigma toward TB by colleagues (TBS-C)
 the stigma management strategy of covering
The interlinked nature of the HIV and TB epidemics
(HIV-TB) was measured by a scale with three items
(“TB is a sign that someone has HIV”; “Someone with
TB has probably also got HIV”; and “TB symptoms
make HIV more noticeable”), each rated on a four point
Likert scale indicating strong agreement, agreement, dis-
agreement, or strong disagreement.
The interlinked nature of the stigmas as defined by the
respondent (the Double Stigma by the Respondent, or
DS-R) was measured by 1 item, namely “Someone who
has TB should feel equally guilty about it as someone
who has HIV,” – also rated on a four-point Likert scale.
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The perceived interlinked nature of HIV and TB
stigmatization by colleagues (perceived Double Stigma
by Colleagues, DS-C) was measured by two items on a
four-point Likert scale (“People are afraid of working to-
gether with someone who has TB because they think
that the person also has HIV” and “People with TB tend
to be treated badly because they may have HIV”).
The study also expects a significant impact on the per-
ceived link between HIV and TB (HIV-TB) and between
the stigmas (DS-R) on the stigmatizing attitudes and be-
havior toward TB. We therefore included a scale meas-
uring the respondent’s stigmatizing attitudes toward TB
(TBS-R, 2 items). In addition, we also expect a signifi-
cant impact on the perceived link between HIV and TB
and between HIV and TB stigmatization by colleagues
(DS-C) on the perceived stigmatizing attitudes and be-
havior toward TB (TBS-C, 5 items) by colleagues. We
consequently also included a scale measuring the col-
leagues’ stigmatizing attitudes toward TB (TBS-C, 2
items). The reliability and validity of these two scales
measuring the respondent’s and colleagues’ stigma to-
ward TB were reported in previous publications - where
TBS-R, TBS-C were respectivelay labelled TB-RES and
TB-OES [39–41].
The social act of “covering” was measured by two
items, namely “If I was diagnosed with HIV then, in
order to hide my HIV status, I would say that I have
TB” and “If I was diagnosed with both TB and HIV I
would only tell that I have TB,” each rated on a four
point Likert scale. This social act is phrased in a condi-
tional manner as we do not know the responding
HCWs’ HIV or TB status.
As we expect that the TB-HIV co-epidemic has linked
TB stigma to HIV stigma, we have to control for (1) re-
spondent’s and (2) colleagues’ stigmatizing attitudes to-
wards HIV. We included two scales measuring the
respondent’s (HIVS-R, 4 items) and the collagues’
(HIVS-C, 4 items) stigmatizing attitudes toward HIV as
we expect a significant impact of the perceived link be-
tween HIV and TB (HIV-TB) and between the stigmas
(DS-R) on (1) the respondent’s and (2) the colleagues’
stigmatizing attitudes and behavior toward HIV.
In order to model social reality as closely as possible, a
number of additional control variables are included in
our analyses. The survey included a series of socio-
demographic questions (age and sex). As we expect dif-
ferences in various dependent variables between HCWs
with medical training (nurses and doctors) and HCWs
without any formal medical training (clerks, cleaners, ad-
ministrators, etc.), this study will also include a measure
of the professional category of the HCW (medical staff
vs non-medical staff). In addition, this study includes the
HIV- (10 items) and TB-related knowledge (10 items) of
the health care workforce as the literature has repeatedly
shown a link between knowledge and stigma [42, 43]. Fi-
nally, previous research [38, 44] clearly indicates that
links exist between stigma and confidentiality. This sur-
vey thus included a question on confidentiality in the
workplace: “In the last 2 years, have you personally ever
witnessed an occupational health nurse in this hospital
failing to keep confidentiality about the health status of
another health care worker? (For example: gossiping
about the health status of a health care worker).” Finally,
the study also controlled for potential hospital effects
arising from the cluster RCT design.
Analytic strategy
Structural equation modeling (SEM) was used to meas-
ure the interrelationships between (1) the perceived
interlinked nature of the two epidemics (HIV-TB), (2)
the reported double stigmatization by the respondent
(DS-R), and (3) the perceived double stigmatization by
colleagues (DS-C) as well as the association of (1), (2),
and (3) with the stigmatization by respondents of (4) TB
(TBS-R) and the perceived stigmatization by colleagues
of (5) TB (TBS-C). Finally, we also tested the impact of
(1) to (5) on the intention to adopt the social act of (6)
covering. All these relationships were controlled for age,
sex, professional category, HIV knowledge, TB know-
ledge, confidentiality, and hospital effects. The concep-
tual model tested in this article is displayed in Fig. 1.
SEM is a combination of confirmatory factor ana-
lysis and multiple regression analyses. First, the meas-
urement model specifies the relationships between the
observed indicators (e.g., the items measuring the re-
spondent’s double stigma) and the overarching latent
variables (for example, the respondent’s double
stigma). Second, the structural model specifies the re-
lationships among the various observed and latent
variables. Following the recommendations of Hu and
Bentler (1999), two of the following three criteria had
to be met for a satisfactory global model fit to be
attained: CFI/TLI ≥ 0.95, RMSEA ≤0.06, and SRMR
≤0.08 [45]. All data analysis was performed using the
statistical software package Mplus version 7.4. The
MLM (maximum likelihood parameter estimates with
standard errors and a mean-adjusted chi-squared test
statistic that are robust to non-normality) method
was used to fit the structural equation models to the
dataset.
Results
Sample characteristics
The characteristics of our sample are depicted in Table 1.
Measurement model
Although SEM is a hybrid of factor analysis and path
analysis, a two-step approach is recommended. Separate
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assessments of the measurement and structural
models prevent the good fit of one model compensat-
ing for (and potentially masking) the poor fit of the
other. The measurement model displays an excellent
fit to the data (RMSEA = .046; CFI = .952; TLI = .941;
and SRMR = .034) (Table 2). The reliability analyses
display excellent consistency of the indicators in
measuring the latent concepts, with Cronbach’s alphas
ranging from .70 to .99. Only the 3-item scale measuring
the interlinked nature of the HIV and TB epidemics
(HIV-TB) displayed borderline consistency, with a Cron-
bach’s alpha of .66. The factor loadings of these three
items were sufficiently high and ranged between .49 and
.74. The two items measuring the perceived interlinked
nature of HIV and TB stigmatization (double stigma) by
colleagues (DS-C) also displayed sufficiently high factor
loadings (λ = .81 and λ = .88). As reported in an earlier
publication, the 4-item scale measuring the respondent’s
stigmatizing attitudes toward HIV (HIVS-R) (λ ranging
from .53 to .75) and the 2-item scale measuring the re-
spondent’s stigmatizing attitudes toward TB (TBS-R)
(λ = .71 and λ = .75) displayed sufficiently high loadings of
the different items onto the factor [39]. Similarly, the 4-
item scale measuring colleagues’ stigmatizing attitudes to-
ward HIV (HIVS-C) (λ ranging from .69 to .72) and the 5-
item scale measuring the colleagues’ stigmatizing attitudes
toward TB (TBS-C) (λ ranging from .64 to .78) displayed
sufficiently high loadings of the different items onto the
factor [39]. Finally, both items measuring the social act of
covering displayed high factor loadings (λ = .85 and
λ = .70). Combined, these findings support the fit of the
measurement model to the data as well as the reliability of
these constructs and their indicators.
Structural model
The RMSEA (0.039) indicates a close fit of the overall
model with reasonable errors of approximation in the
population. Combined with the other goodness-of-fit
statistics (CFI = 0.929; TLI = 0.905; and SRMR = 0.038),
we can conclude that the structural model displays an
acceptable fit to the data (Table 3).
The first section of the model assessed the association
between (1) the interlinked nature of the epidemics
(HIV-TB) and both (2) the interlinked nature of the
Fig. 1 Conceptual model displaying the relationships between the epidemics, links between stigmas, TB stigma, and covering
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stigmas (double stigma) (DS-R) as defined by the re-
spondent and (3) the perceived double stigmatization by
colleagues (DS-C). The reported link between both
epidemics was significantly and positively associated with
the reported link between HIV stigma and TB stigma
(β = .497; P < .000). Respondents who reported a strong
link between HIV and TB also reported a stronger link be-
tween the negative attributes and resulting double
stigmatization of both illnesses. The reported link between
both epidemics was also significantly and positively associ-
ated with the perceived double stigmatization by col-
leagues (β = .425; P < .000). In other words, health care
workers who reported that having TB is a sign of having
Table 1 Sample descriptions
Number Percent
Gender
Male 249 28.3%
Female 631 71.7%
Age (mean, SD) 875 43.62 (9.93)
Professional group
Patient care 446 50.7%
Support staff 434 49.3%
HIV knowledge (mean, SD) 882 6.96 (1.65)
TB knowledge (mean, SD) 882 7.18 (1.52)
Breach in confidentiality 881 20.0%
Link between HIV & TB (HIV-TB)
Item 1 (mean, SD) 882 3.21 (0.77)
Item 2 (mean, SD) 881 2.85 (0.87)
Item 3 (mean, SD) 879 2.52 (0.83)
Double stigma respondent (DS-R)
Item 1 (mean, SD) 881 3.15 (0.74)
Double stigma by colleagues (DS-C)
Item 1 (mean, SD) 880 3.03 (0.77)
Item 2 (mean, SD) 880 3.05 (0.76)
HIV stigma respondent (HIVS-R)
Item 1 (mean, SD) 882 1.87 (0.78)
Item 2 (mean, SD) 882 1.65 (0.76)
Item 3 (mean, SD) 882 1.61 (0.70)
Item 4 (mean, SD) 882 1.50 (0.63)
TB stigma respondent (TBS-R)
Item 1 (mean, SD) 882 1.70 (0.68)
Item 2 (mean, SD) 882 1.80 (0.67)
HIV stigma colleagues (HIVS-C)
Item 1 (mean, SD) 881 1.99 (0.80)
Item 2 (mean, SD) 881 2.13 (0.83)
Item 3 (mean, SD) 880 1.99 (0.74)
Item 4 (mean, SD) 881 2.05 (0.81)
TB stigma colleagues (TBS-C)
Item 1 (mean, SD) 879 1.98 (0.74)
Item 2 (mean, SD) 880 1.96 (0.72)
Item 3 (mean, SD) 879 2.12 (0.84)
Item 4 (mean, SD) 879 2.00 (0.77)
Item 5 (mean, SD) 880 2.91 (0.80)
Covering
Item 1 (mean, SD) 882 3.06 (0.79)
Item 2 (mean, SD) 881 3.00 (0.80)
Table 2 Item analysis, goodness-of-fit, and reliability assessment
of the measurement model (n = 874)
Scales Standardized loadings (λ) P
Link between HIV & TB (HIV-TB)
Item 1 0.737 < 0.001
Item 2 0.663 < 0.001
Item 3 0.486 < 0.001
Double stigma by colleagues (DS-C)
Item 1 (mean, SD) 0.814 < 0.001
Item 2 (mean, SD) 0.875 < 0.001
HIV stigma respondent (HIVS-R)
Item 1 (mean, SD) 0.527 < 0.001
Item 2 (mean, SD) 0.734 < 0.001
Item 3 (mean, SD) 0.752 < 0.001
Item 4 (mean, SD) 0.742 < 0.001
TB stigma respondent (TBS-R)
Item 1 (mean, SD) 0.711 < 0.001
Item 2 (mean, SD) 0.754 < 0.001
HIV stigma colleagues (HIVS-C)
Item 1 (mean, SD) 0.720 < 0.001
Item 2 (mean, SD) 0.686 < 0.001
Item 3 (mean, SD) 0.699 < 0.001
Item 4 (mean, SD) 0.689 < 0.001
TB stigma colleagues (TBS-C)
Item 1 (mean, SD) 0.728 < 0.001
Item 2 (mean, SD) 0.782 < 0.001
Item 3 (mean, SD) 0.685 < 0.001
Item 4 (mean, SD) 0.643 < 0.001
Item 5 (mean, SD) 0.733 < 0.001
Covering
Item 1 (mean, SD) 0.851 < 0.001
Item 2 (mean, SD) 0.704 < 0.001
Goodness of fit
RMSEA 0.046
CFI 0.952
TLI 0.941
SRMR 0.034
Wouters et al. BMC Infectious Diseases          (2020) 20:106 Page 6 of 12
HIV were more likely to report that co-workers stigmatize
people with TB because of HIV-related reasons. Con-
versely, TB knowledge was negatively associated with the
perceived double stigmatization by colleagues (β = −.128;
P < .005): health care workers with higher levels of TB
knowledge were less likely to perceive a transfer of the
stigmatizing attitudes toward HIV to TB among their col-
leagues. Finally, witnessing a breach in confidentiality at
the sick bay was positively associated with the perceived
link between HIV stigma and TB stigma by the respond-
ent (β = .069; P < .05). None of the other control variables
was significantly linked to these two 2 outcomes.
The second section explored whether (1) the link be-
tween the epidemics (HIV-TB), (2) the reported link be-
tween the stigmas (DS-R), and (3) the perceived link
between the stigmas by colleagues (DS-C) are associated
with the stigmatization of TB – in other words, how the
link between the illnesses and the link between their
stigmas is reflected in the stigmatization of TB. We
assessed the association of these 3 aspects of the co-
epidemic with (1) the stigmatization of TB by the re-
spondent (TBS-R) and (2) the perceived stigmatization
of TB by colleagues (TBS-C).
First, the link between the epidemics (β = .238;
P < .001), the double stigma (as reported by the respond-
ent) (β = .152; P < .005), and the perceived double stigma
by colleagues (β = .430; P < .001) were significantly asso-
ciated with the stigmatizing attitudes and behaviors of
the responding HCW toward TB: it is clear that the
stigma toward TB is strongly associated with the co-
epidemic and its resulting double stigma. Respondents
who reported that TB is a sign of having HIV, who
linked the two stigmas, and who perceived that col-
leagues linked the 2 stigmas were significantly more
likely to stigmatize TB. Age (β = .085; P < .05), less TB
knowledge (β = −.105; P < .01), and witnessing a breach
in confidentiality (β = .078; P < .05) were also signifi-
cantly associated with TB stigma: older HCWs with
lower levels of knowledge of TB were more likely to re-
port stigmatizing attitudes and behaviors toward TB.
Table 3 Standardized Mplus coefficients (β) and model summary of the structural model (n = 862)
Link between stigmas Separate stigmas Management
DS-R DS-C TBS-R TBS-C HIVS-R HIVS-C Covering
HIV-TB 0.497*** 0.425*** 0.238*** 0.062 0.178** −0.024 0.235***
DS-R 0.152*** 0.059 0.078 0.014 0.038
DS-C 0.430*** 0.611*** −0.040 0.571*** 0.085
TBS-R 0.402***
TBS-C − 0.234*
Control variables:
HIVS-R − 0.005
HIVS-C 0.352***
Age − 0.000 − 0.004 0.085 − 0.036 0.050 0.000 0.051
Sex −0.003 −0.051 0.068 − 0.018 0.048 − 0.009 0.072*
Professional category −0.190 0.017 0.064 0.016 0.058 0.033 0.023
TB knowledge 0.004 −0.128** − 0.105** −0.013 − 0.099* 0.014 0.056
HIV knowledge −0.051 0.004 −0.019 −0.010 − 0.095* 0.044 − 0.042
Confidentiality 0.069* 0.061 0.078* 0.148*** 0.016 0.179*** −0.011
Hospital (Ref = 1)
Hospital 2 −0.054 −0.041 − 0.034 −0.066* 0.001 −0.007 0.009
Hospital 3 −0.002 0.005 −0.089 −0.009 − 0.023 −0.041 − 0.024
Hospital 4 −0.028 0.009 −0.017 − 0.008 −0.085 0.012 0.013
Hospital 5 −0.014 0.015 −0.001 0.001 0.002 0.050 0.013
Hospital 6 0.019 −0.027 − 0.012 0.014 − 0.055 −0.007 − 0.046
Hospital 7 0.028 −0.029 −0.111** − 0.033 −0.083* − 0.023 0.079*
Hospital 8 0.035 0.004 −0.099** −0.027 − 0.005 −0.019 0.084*
Goodness of fit
RMSEA 0.039 TLI 0.905
CFI 0.929 SRMR 0.038
*P < .05; **P < .01; ***P < .001
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None of the other control variables – apart from a few
hospital effects – were significantly linked to TB stigma.
Second, the perceived link between the stigmatization
toward HIV and TB by colleagues was significantly asso-
ciated with the corresponding TB stigma type, namely
the perceived stigmatization toward TB by colleagues
(β = .611; P < .001). There was thus a very strong associ-
ation between the perceived double stigma and the sep-
arate TB stigma. Witnessing a breach in confidentiality
at the sick bay was also significantly associated with the
perceived stigmatization toward TB (β = .148; P < .001)
by colleagues. None of the other control variables was
significantly linked to TB stigmatization by colleagues.
When looking at the relationships with the
stigmatization towards HIV (by the respondent and by
colleagues) – one of our most important control vari-
ables – we observe that the reported link between HIV
and TB (HIV-TB) was positively associated with HIV
stigmatization by the interviewed HCW (HIVS-R)
(β = .178; P < .005). HCWs who reported that TB is a
sign of having HIV were more likely to report stigmatiz-
ing attitudes and behaviors toward HIV. Having more
HIV (β = −.095; P < .05) and TB (β = −.099; P < .05)
knowledge was negatively associated with stigmatizing
attitudes toward HIV: HCWs who knew more about
HIV and TB were less likely to stigmatize HIV-positive
colleagues. In accordance with the findings on TB
stigma, the perceived link between the stigmatization
toward HIV and TB by colleagues was significantly asso-
ciated with the corresponding HIV stigma types, namely
(1) the perceived stigmatization toward HIV by col-
leagues (β = .571; P < .001). Witnessing a breach in confi-
dentiality at the sick bay was also significantly associated
with the perceived stigmatization toward HIV (β = .179;
P < .001) by colleagues.
The structural model also includes the correlates of
the social act of covering. Covering was significantly as-
sociated with (1) sex, (2) the reported link between HIV
and TB (HIV-TB), (3) the stigmatization of TB (TBS-R),
(4) the perceived stigmatization of TB by colleagues
(TBS-C), and (5) the perceived stigmatization of HIV by
colleagues (HIVS-C).
Being female (β = .106; P < .05) weakly but significantly
increased the odds of using TB as an excuse for having
HIV when being confronted by these illnesses. HCWs
who recognized having TB as a sign of having HIV (link
between both epidemics) were significantly more likely
(β = .235; P < .001) to employ TB as a cover for HIV
when they become infected HIV (or both HIV and TB).
Thirdly, there was a strong link (β = .351; P < .005) be-
tween the self-reported stigmatization of TB and the re-
ported likelihood of using TB as cover for having HIV:
HCWs who displayed higher levels of TB stigma were
significantly more likely to resort to covering when they
were HIV-positive. There was a strong positive link be-
tween the stigmatization toward TB and the likelihood
of adopting the social act of covering (β = .402; P < .001):
against expectations, HCWs with stigmatizing attitudes
toward TB were significantly more likely to cover an
HIV-positive diagnosis with the label of having TB. The
perceived TB stigmatizing behavior by colleagues was, as
expected, negatively associated with covering (β = −.233;
P < .05): if HCWs responded that their colleagues stig-
matized TB more, they were significantly less likely to
employ TB as a cover for HIV. Correspondingly the per-
ceived HIV stigmatizing behavior by colleagues was
positively associated with covering (β = .350; P < .001): if
HCWs responded that their fellow HCWs stigmatized
HIV more, they were significantly more likely to use TB
as a cover for HIV.
Discussion
Sub-Saharan Africa at large and South Africa in particu-
lar is confronted with a devastating HIV/TB-co-epi-
demic. Little is known, however, of the creation and
dynamics of double stigma in the context of these inter-
twined epidemics and the impact of this double stigma
on the social connotations of TB. The current study ad-
dressed this research gap by explicitly exploring how (1)
the interlinked nature of HIV and TB and (2) the result-
ing double stigmatization of HIV-TB (by the respondent
and by colleagues) have changed the stigmatization TB
and the resulting stigma management strategy of (4)
covering.
As previously reported in the qualitative work of
Daftary (2012) and Bond and Nyblade (2006), the
interwovenness of HIV and TB, reflecting the bio-
medical reality of HIV-TB co-infection, has resulted
in the creation of a new form of compound or double
stigma [9, 26]. The results of the analysis clearly indi-
cate that the link between both illnesses is reflected
in an additional layer of stigmatization, that of the
transfer of stigmatizing attitudes and behaviors previ-
ously linked to HIV and TB. It was clearly demon-
strated that the perceived link between the epidemics
was reflected in the creation of a double stigma,
reflected in both (1) a self-reported link between both
stigmas and (2) a perceived linking of both stigmas
by fellow HCWs. The study thus provides quantitative
evidence of the linking of both illnesses and resulting
stigmas previously reported in exploratory qualitative
studies [9, 26].
The current study went a step further by subsequently
exploring the link between this double stigma and the
stigmatization of TB. As expected, the link between the
epidemics and the associated double stigma has resulted
in the increased stigmatization of TB. To the best of our
knowledge, this is the first quantitative study to
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demonstrate the empirical link between the interwoven-
ness of HIV and TB and the stigmatization of TB with
the associated compound or double stigma as an import-
ant mediating variable. The results offer an evidence-
based explanation of why TB-associated stigma has de-
clined in low HIV-prevalence communities but resurged
in high-burden settings during the past decade [9, 46].
Finally, this study explored the drivers of the stigma
management strategy of covering, whereby people living
with HIV attempt to avoid or minimize discrimination
by using a lesser stigmatized illness, TB, as a cover for
HIV. Our findings indicate that the perceived interlinked
nature of the two epidemics clearly drives this stigma
management strategy. In line with previous research [9],
HCWs who recognize the link between HIV and TB are
more likely to employ covering as a way to minimize
HIV-related discrimination. It is thus evident that the
co-epidemic and its repercussions for the stigmatization
of HIV and TB impact the behavior of those affected.
In contrast with expectations, stigmatizing attitudes
against TB increased the likelihood of employing the
stigma management strategy of covering, meaning that
one would employ TB as a cover for HIV. However, this
can be explained by the fact that, as indicated above, a
large part of the variability in TB stigma can be ascribed
to the transfer of discriminatory attitudes against HIV to
individuals with TB. This was also shown in the qualita-
tive work of Mavhu et al. (2010) and Ngamvithayapong
et al. (2000) [47, 48]. Those who stigmatize TB are thus
those who recognize the link between both epidemics
and potentially see covering as a vital or effective strategy
to avoid HIV stigmatization. Conversely, it is also possible
that we have a case of reversed causality: it is possible that
those HCWs viewing sharing a (fictitious) TB diagnosis as
a potential strategy to cover for HIV, are transfering stig-
matizing attitudes toward HIV to TB, thereby displaying
increased levels of TB stigma. The fact that TB stigma for
many respondents seems almost synonymous with the
double stigma as the stigmatization of TB is largely attrib-
utable to its link with HIV renders it virtually impossible
to singularize the relationship between TB stigma and
covering in abstraction of the link with HIV.
In line with expectations, the perceived stigmatizing
attitudes of colleagues toward TB were strongly associ-
ated with the likelihood of employing covering as a strat-
egy to deal with a positive HIV diagnosis. The stronger
the dominant stigma associated with HIV and the
weaker the stigma associated with TB, the more likely
HCWs were to resist discrimination by using TB as a
cover for HIV. Our results demonstrate that the stigma-
tizing attitudes toward HIV by colleagues clearly push
HCWs toward potentially deflecting “attention away
from a dominant stigmatizing attribute (that is, HIV) by
drawing attention to something more socially acceptable
(that is, TB)” [9]. Our results also support the statements
of Mbonu et al. (2009) who concluded in their system-
atic study that “people prefer to claim that they are
bewitched or have (normal) tuberculosis rather than
accept that they have HIV/AIDS” [49]. Our study is the
first large-scale quantitative study to confirm these ex-
ploratory qualitative findings.
This study’s strengths include: (1) its theoretical foun-
dation in stigma literature, (2) its large-scale quantitative
design, (3) the availability of well-developed scales to
measure different types of stigma (TB, HIV, and double
stigma), and (4) the availability of information on an
understudied population, namely HCWs active in a vul-
nerable health system burdened by the HIV/TB co-
epidemic. To the best of our knowledge, this is the first
study to quantitatively disentangle the complex interrela-
tionships between the interlinked nature of the epi-
demics, the interlinked nature of the stigmas, the
distinct HIV- and TB-related stigmas, and the resulting
stigma management strategy (covering). We empirically
tested and confirmed the theory-building findings of
previous in-depth qualitative studies on this topic.
This study had several limitations. First, it focused on
the stigma management strategy of covering, which has
emerged as one of the most relevant stigma manage-
ment strategies in the context of the co-epidemic. Other
stigma management strategies (for example, “othering,”
the symbolic distancing from persons affected by HIV)
were not examined; future studies should incorporate
these alternative stigma management strategies. Second,
although cross-lagged regression would have been more
appropriate, the study was limited to cross-sectional ana-
lyses as the follow-up data of the cluster RCT were not
yet available. We were therefore unable to make any at-
tributions of causal influence among the different inde-
pendent variables and stigma outcomes. Third, this
study collected data on a random sample of HCWs ac-
tive in the 8 selected hospitals, irrespective of their HIV
status or TB history, thus gathering data on their stigma
management strategies in the hypothetical case of a TB/
HIV co-infection. Fourth, this study did not explore
stigma related to drug-resistant TB (MDR-TB), which is
known to have distinct and more severe manifestations
disturbing the examined relationships between HIV and
TB stigma and the resulting management strategy. Given
these shortcomings, future longitudinal, large-scale stud-
ies collecting data on a random sample of co-infected
people with a specific focus on MDR-TB are needed to
confirm and potentially expand knowledge on the dem-
onstrated interrelationships.
Conclusions
The results of this study have both theoretical and prac-
tical relevance. From a theoretical perspective, this is the
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first study to use a large-scale dataset to empirically dis-
entangle the interrelationships between HIV, TB, HIV
stigma, TB stigma, and double stigma. The results dem-
onstrate that, as hypothesized by previous qualitative
work, the co-epidemic (and especially the link with the
discredited HIV status) is driving the stigmatization to-
ward TB. Consequently, the findings extend our under-
standing of the social ramifications of the co-epidemic
by empirically supporting the theorization of double
stigma and the resulting management of the two inter-
linked illness-related identities in the context of the dev-
astating HIV-TB co-epidemic.
These insights help to inform appropriate responses
from the health care system: from a practical and policy
perspective, the results urge policymakers to strengthen
integrated measures, as the interlinked nature of the epi-
demics and the associated stigmas demonstrate that ver-
tical programs inevitably ignore a significant part of the
reality of an HIV or TB diagnosis. The results urge pol-
icymakers to merge the often-contrasting cultures of
HIV care, a patient-centered, individualized approach,
and TB care characterized by a traditional public health
approach [8, 50, 51]. The proposed integrated approach
should recognize the intertwined nature of the HIV-TB
co-epidemic, not only in medical-clinical terms, but also
in its social consequences. The established rise in TB
stigma caused by the perceived links between HIV and
TB and the resulting double stigma however also urge
health policy makers to not blindly intergrate HIV and
TB care as this may increase TB stigma levels. The
current push towards integration [52, 53] thus needs to
be complemented with interventions that recognize and
take into account the interlinked nature of the epi-
demics, which cannot be separated in a context where 3
out of every 4 TB cases are HIV-positive [27, 50]. Our
findings and the associated overarching HaTSaH study
testing an intervention to address HIV and TB stigma
among HCWs aligns with the ongoing START study by
Howard et al. [54] that explicitly aimed to evaluate the
effectiveness of a combination intervention package to
improve ART uptake and adherence during TB treat-
ment in Lesotho. More research is needed to translate
the knowledge of the social ramifications of the co-
epidemic into evidence-based interventions that can
optimally combat the co-epidemic and not only reduce
the risk of transmission (and the resulting burden of dis-
ease), but also create a health-enabling environment in
which HCWs affected by HIV and/or TB are optimally
treated and supported [11, 55].
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